Alzamend Neuro

ALZN · Nasdaq · United States

Share price · ALZN

$1.04-0.48 (-31.58%) 3M

close as of 2026-11-18 · 24h delayed · vol 38K (1.1x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ALZN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 6 Nov 2026-9.0%

    Nothing announced by ALZN that day or the session before.

  2. 3 Nov 2026+16.8%

    Nothing announced by ALZN that day or the session before.

  3. 22 Oct 2026-10.4%

    Nothing announced by ALZN that day or the session before.

  4. 1 Oct 2026-24.0%

    Nothing announced by ALZN that day or the session before.

  5. 20 Aug 2026+7.2%
  6. 26 Jun 2026-7.0%

    Nothing announced by ALZN that day or the session before.

  7. 20 May 2026+18.8%

    Nothing announced by ALZN that day or the session before.

  8. 14 Apr 2026+15.7%

    Nothing announced by ALZN that day or the session before.

  9. 27 Mar 2026-30.0%
  10. 26 Mar 2026-22.3%

Share of unusual movement by asset

For each asset, the share of ALZN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Lithium salicylate/L-proline (AL001)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—2%
Other company news (earnings, financing, releases naming no asset)—4%
Sessions with no dated event—93%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 1/2
—Small molecule
Alzheimer's DiseaseBipolar Disorder

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
2026-10-31 Financial ReportEarnings report
Expected report date 2026-12-08 · Fiscal period ending 2026-10-31
What to watch
2027 (1)
July 2027 (1)
Lithium salicylate/L-proline (AL001)Phase 1/2Bipolar I Disorder
Est. primary completion 2027-07 · NCT07540338 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

26 March 2026Topline resultAL001Phase II 'Lithium in Brain' study of AL001 achieved bioequivalence with lithium carbonate
Alzamend Neuro · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$1.1M$7.6M$3.0M-$1.1M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1—$1.3M$2.7M$2.2M-$1.7M operating cash flowreport ↗
2025-Q4—$0.2M$4.5M$1.0M-$1.2M operating cash flowreport ↗
2025-Q3—$1.7M$5.6M$2.7M-$2.4M operating cash flowreport ↗
2025-Q1—$0.5M$3.4M$1.0M-$1.4M operating cash flowreport ↗
2024-Q4—$0.3M$4.1M$1.4M-$3.4M operating cash flowreport ↗
2024-Q3—$0.2M$1.2M$1.0M-$1.1M operating cash flowreport ↗
2024-Q1—$1.9M$0.3M$2.7M-$2.0M operating cash flowreport ↗
2023-Q4—$2.0M$0.2M$2.9M-$1.5M operating cash flowreport ↗
2023-Q3—$2.4M$1.7M$3.5M-$3.3M operating cash flowreport ↗
2023-Q1—$2.9M$7.4M$5.4M-$1.8M operating cash flowreport ↗
2022-Q4—$1.5M$9.2M$3.1M-$2.3M operating cash flowreport ↗
2022-Q3—$1.4M$12M$3.0M-$2.5M operating cash flowreport ↗
2022-Q1—$0.9M$12M$2.6M-$1.8M operating cash flowreport ↗
2021-Q4—$1.8M—$3.6M-$2.0M operating cash flowreport ↗
2021-Q3—$0.9M—$2.3M-$1.2M operating cash flowreport ↗

Annual history (6 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-FY—$3.6M$0.7M$2.2M-$8.1M operating cash flowreport ↗

Alzamend Neuro’s fiscal 2026 report (ended April 30, 2026) disclosed no revenue for the current or prior year. R&D spend was $3.63M, up 157.4% YoY, with cash and equivalents of $0.71M. The company reported a net loss of $8.77M and a quarterly net burn of $8.77M.

The clinical-stage biopharmaceutical company advanced its lead candidate AL001, reporting PK and PD topline data from the healthy-subject Lithium in Brain study and initiating a Phase II trial in bipolar disorder, with topline data expected in the fourth quarter of 2026. Full PK/PD results are expected in August 2026, MDD and PTSD trials are expected to commence in the fourth quarter of 2026, an Alzheimer’s trial is expected to begin in the first quarter of 2027, and the ALZN002 Phase I/IIA trial is expected to restart in the first quarter of 2027.

View 5 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$1.4M$4.0M$1.1M-$6.6M operating cash flowreport ↗
2024-FY—$6.5M$0.4M$2.5M-$8.3M operating cash flowreport ↗
2023-FY—$7.5M$5.1M$3.7M-$8.9M operating cash flowreport ↗
2022-FY—$5.2M$14M$3.1M-$6.6M operating cash flowreport ↗
2021-FY—$1.3M$1.9M$1.3M-$2.7M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 5 purchases ($331K), 3 sales ($14K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-26AULT MILTON C III · directorOpen-market sale2,000$1.56$3KForm 4
2026-07-31Hyperscale Data, Inc.; Ault Lending, LLC; Ault Capital Group, Inc. · director; director; directorAward / grant (derivative)7,500$1000.00$7.5MForm 4
2026-07-31AULT MILTON C III · directorAward / grant (derivative)7,500$1000.00$7.5MForm 4
2026-07-31Hyperscale Data, Inc. · directorAward / grant (derivative)7,500$1000.00$7.5MForm 4
2026-04-14AULT MILTON C III · directorOpen-market purchase108,388$1.00$109KForm 4
2026-04-14AULT MILTON C III · directorOpen-market purchase108,388$1.00$109KForm 4
2026-04-14AULT MILTON C III · directorOpen-market purchase2,000$1.03$2KForm 4
2026-04-14AULT MILTON C III · directorOpen-market purchase2,000$1.03$2KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 12 reporting institutions held 0.1M shares ($122K, 2.4% of shares outstanding).

#InstitutionSharesValue
1GEODE CAPITAL MANAGEMENT, LLC45,680$48K
2VANGUARD FIDUCIARY TRUST CO21,020$22K
3MORGAN STANLEY18,000$19K
4Clearstead Advisors, LLC10,000$11K
5Tower Research Capital LLC (TRC)6,184$7K
6CITIGROUP INC5,231$6K
7UBS Group AG4,504$5K
8VANGUARD CAPITAL MANAGEMENT LLC4,400$5K
9BlackRock, Inc.437$463
10SBI Securities Co., Ltd.22$23
11Caitong International Asset Management Co., Ltd4$4
12HARBOR INVESTMENT ADVISORY, LLC1$1